Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Molecular Genetics and Metabolism

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ymgme.2015.11.001PMID 26597321
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Newborn Screening for Lysosomal Storage Disorders

  2016cited by this paper
• Measuring relative lysosomal volume for monitoring lysosomal storage diseases.

  2015cited by this paper
• Immune tolerance strategies in siblings with infantile Pompe disease — Advantages for a preemptive approach to high-sustained antibody titers

  2015cited by this paper
• CRIM-negative infantile Pompe disease: Characterization of immune responses in patients treated with ERT monotherapy

  2015cited by this paper
• Antibody‐Mediated Rejection in Kidney Transplantation: A Review of Pathophysiology, Diagnosis, and Treatment Options

  2014cited by this paper
• Letter to the Editors: Concerning “CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy” by Al Khallaf et al

  2014cited by this paper
• Newborn screening for lysosomal storage disorders and other neuronopathic conditions.

  2013cited by this paper
• Considering Fabry, but Diagnosing MPS I: Difficulties in the Diagnostic Process.

  2013cited by this paper
• Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

  2013cited by this paper
• IgE‐mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome

  2013cited by this paper
• Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy

  2013cited by this paper
• Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT

  2013cited by this paper
• Enzyme-Replacement Therapies for Lysosomal Storage Diseases

  2013cited by this paper
• The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.

  2013cited by this paper
• Immune modulation in Pompe disease treated with enzyme replacement therapy

  2012cited by this paper
• The impact of antibodies in late-onset Pompe disease: a case series and literature review.

  2012cited by this paper
• Predicting cross‐reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experience

  2012cited by this paper
• Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice

  2012influential reference
• Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease

  2012cited by this paper
• Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease

  2012cited by this paper
• The emerging phenotype of long-term survivors with infantile Pompe disease

  2012cited by this paper
• Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome

  2012cited by this paper
• Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).

  2011cited by this paper
• The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease

  2011cited by this paper
• Clarifying lysosomal storage diseases.

  2011cited by this paper
• [Immune tolerance induction with high-dose FVIII and pulsed intravenous immunoglobulin].

  2010cited by this paper
• Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.

  2010cited by this paper
• Common and Uncommon Pathogenic Cascades in Lysosomal Storage Diseases*

  2010cited by this paper
• A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.

  2009cited by this paper
• Elimination of antibodies to recombinant enzyme in Pompe's disease.

  2009cited by this paper
• Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?

  2009cited by this paper
• Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I

  2009cited by this paper
• Lysosomal disorders: from storage to cellular damage.

  2009cited by this paper
• A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I.

  2009cited by this paper
• Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders.

  2009cited by this paper
• Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease

  2009cited by this paper
• Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

  2008cited by this paper
• Successful Management of Difficult Infusion-Associated Reactions in a Young Patient With Mucopolysaccharidosis Type VI Receiving Recombinant Human Arylsulfatase B (Galsulfase [Naglazyme])

  2008cited by this paper
• Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease

  2008cited by this paper
• Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease.

  2008cited by this paper
• Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.

  2008cited by this paper
• Enzyme replacement therapy with agalsidase alfa in children with Fabry disease

  2007cited by this paper
• Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis I and Are Younger Than 5 Years: Results of a Multinational Study of Recombinant Human α-l-Iduronidase (Laronidase)

  2007influential reference
• Enzyme-Replacement Therapy With Agalsidase Alfa in Children With Fabry Disease

  2006cited by this paper
• Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.

  2006cited by this paper
• Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.

  2006cited by this paper
• Newborn screening for lysosomal storage disorders.

  2006cited by this paper
• Genetic risk factors for inhibitors to factors VIII and IX

  2006cited by this paper
• Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.

  2004cited by this paper
• Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.

  2003influential reference
• Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

  2001cited by this paper
• Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

  2001cited by this paper
• Prevalence of lysosomal storage disorders.

  1999cited by this paper
• Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats.

  1999cited by this paper
• Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase.

  1997cited by this paper

• AAV Gene Therapy for MPS IVA with Induction of Immune Tolerance via Oral Administration of Epitope Peptides of N-Acetylgalactosamine-6-sulfate Sulfatase

  2026cites this paper
• A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry disease

  2026cites this paper
• Current regulatory requirements for assessment of immunogenicity for gene therapy medicinal products

  2025cites this paper
• Management of hypersensitivity in a patient with late-onset Pompe disease experiencing recurrent infusion-related reactions

  2025cites this paper
• A Semi-Mechanistic Mathematical Model of Immune Tolerance Induction to Support Preclinical Studies of Human Monoclonal Antibodies in Rats

  2025cites this paper
• Engineering Mesenchymal Stem Cells with Antioxidant Catalase‐Loaded Metal–Organic Frameworks for Targeted Spinal Cord Injury Therapy

  2025cites this paper
• Cardiovascular involvement in glycogen storage diseases

  2025influential citation
• Prenatal Delivery of Enzyme Replacement Therapy to Fetuses Affected by Early‐Onset Lysosomal Storage Diseases

  2025influential citation
• Current status of the immunogenicity of enzyme replacement therapy in fabry disease

  2025cites this paper
• Current and Emerging Therapies for Lysosomal Storage Disorders.

  2025cites this paper
• Current Concepts in the Management of Sanfilippo Syndrome (MPS III): A Narrative Review

  2024cites this paper
• Expert opinion on clinical presentation, diagnosis, and treatment of infantile-onset Pompe disease: a Delphi study in Türkiye

  2024influential citation
• Dose-intensive therapy (DIT) for infantile Pompe disease: A pilot study

  2024cites this paper
• The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II)

  2024cites this paper
• Desensitization of olipudase alfa-induced anaphylaxis in a child with chronic neurovisceral acid sphingomyelinase deficiency

  2024cites this paper
• Advances in Immune Tolerance Induction in Enzyme Replacement Therapy

  2024cites this paper
• Unlocking potential diabetes therapeutics: Insights into alpha-glucosidase inhibition

  2024cites this paper
• Expert-opinion-based guidance for the care of children with lysosomal storage diseases during the COVID-19 pandemic: An experience-based Turkey perspective

  2023cites this paper
• Intrauterine enzyme replacement therapies for lysosomal storage disorders: Current developments and promising future prospects

  2023influential citation
• Hydrogel Delivery Device for the In Vitro and In Vivo Sustained Release of Active rhGALNS Enzyme

  2023cites this paper
• Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA

  2023cites this paper
• Optimizing human α-galactosidase for treatment of Fabry disease

  2023cites this paper
• Polymer-Based Drug Delivery Systems Under Investigation For Enzyme Replacement And Other Therapies Of Lysosomal Storage Disorders.

  2023cites this paper
• The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?

  2022cites this paper
• A kaleidoscopic view of extracellular vesicles in lysosomal storage disorders

  2022cites this paper
• Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy

  2022cites this paper
• In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease.

  2022cites this paper
• Mucopolysaccharidoses and the blood–brain barrier

  2022cites this paper
• Enzyme replacement therapy: current challenges and drug delivery prospects via extracellular vesicles

  2022cites this paper
• Therapeutic Strategies For Tay-Sachs Disease

  2022cites this paper
• Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis

  2022cites this paper
• Lysosomal storage disorders with neurological manifestations

  2022cites this paper
• Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel

  2022influential citation
• Long-term safety and efficacy of agalsidase beta in Japanese patients with Fabry disease: aggregate data from two post-authorization safety studies

  2021influential citation
• The Mucopolysaccharidoses: Prenatal Diagnosis, Neonatal Screening and Emerging Therapies

  2021cites this paper
• Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease

  2021influential citation
• Mucopolysaccharidosis III: Molecular basis and treatment

  2021cites this paper
• Persistent dyslipidemia in treatment of lysosomal acid lipase deficiency

  2020cites this paper
• An evaluation of the efficacy of allogeneic hematopoietic stem cell transplantation in patients with mucopolysaccharidosis type I (Hurler syndrome): the experience of the R.M. Gorbacheva Research Institute for Pediatric Oncology, Hematology and Transplantation

  2020cites this paper
• Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome

  2020cites this paper
• Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models

  2020cites this paper
• Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort

  2020cites this paper
• Management of Hypersensitivity Reactions to Enzyme Replacement Therapy in Children with Lysosomal Storage Diseases.

  2020cites this paper
• Anti-Taliglucerase Alpha Antibodies Associated with Lower Efficacy of ERT and Onset of Autoimmune Thyroiditis in a Patient with Type 1 Gaucher Disease

  2020cites this paper
• Sanfilippo Syndrome: Molecular Basis, Disease Models and Therapeutic Approaches

  2020influential citation
• A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I.

  2020cites this paper
• Оценка эффективности аллогенной трансплантации гемопоэтических стволовых клеток при мукополисахаридозе I типа (cиндром Гурлер): опыт НИИ ДОГиТ им. Р.М. Горбачевой

  2020cites this paper
• Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin America

  2020cites this paper
• Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy

  2019cites this paper
• Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease

  2019cites this paper
• Improving diagnosis and treatment outcomes in mucopolysaccharidoses

  2019cites this paper
• Practical management of lysosomal storage disorders (LSDs)

  2019cites this paper
• Autophagy in the Central Nervous System and Effects of Chloroquine in Mucopolysaccharidosis Type II Mice

  2019cites this paper
• Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome.

  2019cites this paper
• Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I

  2019influential citation
• Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis

  2019cites this paper
• Study of Intraventricular Cerliponase Alfa for CLN2 Disease

  2018cites this paper
• Infantile‐onset Pompe disease: A case series highlighting early clinical features, spectrum of disease severity and treatment response

  2018cites this paper
• Cryo-EM structure of the mitochondrial calcium uniporter

  2018cites this paper
• Sphingolipidoses and Related Disorders

  2018cites this paper
• Causal Therapies in Mucopolysaccharidoses: Enzyme Replacement Therapy

  2018cites this paper
• Validation of an Immunoassay for Anti-thymidine Phosphorylase Antibodies in Patients with MNGIE Treated with Enzyme Replacement Therapy

  2018cites this paper
• An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease

  2018cites this paper
• Enzyme replacement therapies: what is the best option?

  2018cites this paper
• Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY

  2018cites this paper
• Immune modulation in a patient with Morquio syndrome treated with enzyme replacement therapy.

  2018cites this paper
• Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease.

  2017cites this paper
• Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives

  2017cites this paper
• Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story

  2017cites this paper
• Investigation of Vesicular-Mediated Transport of Intercellular Adhesion Molecule-1-Targeted Carriers for Treatment of Lysosomal Storage Disorders

  2017cites this paper
• A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I

  2017cites this paper
• Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease

  2017cites this paper
• Ten-year-long enzyme replacement therapy shows a poor effect in alleviating giant leg ulcers in a male with Fabry disease

  2017cites this paper
• Cell based assay identifies TLR2 and TLR4 stimulating impurities in Interferon beta

  2017cites this paper
• Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum

  2017cites this paper
• Modulating the immune system through nanotechnology.

  2017cites this paper
• Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report,

  2017influential citation
• Delayed Infusion Reactions to Enzyme Replacement Therapies.

  2016cites this paper
• Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients

  2016cites this paper
• Disease models for the development of therapies for lysosomal storage diseases

  2016cites this paper
• Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.

  2016cites this paper
• The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders

  2016cites this paper